Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

Trial Profile

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Telotristat etiprate (Primary)
  • Indications Biliary cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms TELE-ABC
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 03 Dec 2019 According to a Lexicon Pharmaceuticals media release, the company looks forward to obtaining the topline data on progression-free survival for the first 20 biliary tract cancer patients next year.
    • 03 Dec 2019 According to a Lexicon Pharmaceuticals media release, the company has completed a safety reveiew of the initial run-in cohort of this study.
    • 20 Aug 2019 Planned number of patients changed from 54 to 53.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top